INT55699

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 1994
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.91
Pain Relevance 1.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (DIO2) plasma membrane (DIO2) cellular nitrogen compound metabolic process (DIO2)
Anatomy Link Frequency
neurons 2
DIO2 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 64 97.20 Very High Very High Very High
antagonist 68 96.88 Very High Very High Very High
Arthritis 1 90.00 High High
dopamine receptor 18 89.36 High High
Dopamine 184 87.84 High High
interstitial cystitis 3 80.40 Quite High
Thalamus 4 77.48 Quite High
Inflammatory mediators 2 77.16 Quite High
Pain 3 75.08 Quite High
Inflammation 1 75.00 Quite High
Disease Link Frequency Relevance Heat
Necrosis 3 100.00 Very High Very High Very High
Cancer 3 100.00 Very High Very High Very High
Movement Disorders 14 98.32 Very High Very High Very High
Renal Disease 1 91.64 High High
Diabetes Mellitus 1 90.40 High High
Arthritis 1 90.00 High High
Tremor 22 84.04 Quite High
Interstitial Cystitis 3 80.40 Quite High
INFLAMMATION 3 76.76 Quite High
Pain 1 75.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Urinary concentrations of tumor necrosis factor, prostaglandins E2, D2 and F2 alpha, and thromboxane B2 were not different among either patient groups or controls.
Neg (not) Regulation (different) of D2 Binding (concentrations) of associated with necrosis and cancer
1) Confidence 0.24 Published 1994 Journal J. Urol. Section Abstract Doc Link 8015071 Disease Relevance 1.38 Pain Relevance 0.42
Thus the single nigral axon may influence both D1 and D2 receptors in the pool of striatal neurons responsible for movement activity of agonist–antagonist muscle pair.
Spec (may) Regulation (influence) of D2 Binding (receptors) of in neurons associated with antagonist and agonist
2) Confidence 0.24 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0 Pain Relevance 0.49
At the molecular biology and neuropharmacological levels, the hypothesis suggests that putative treatments need to consider both D1 and D2 activity for maximal therapeutic efficacy in most movement disorders.



Regulation (consider) of D2 Binding (activity) of associated with movement disorders
3) Confidence 0.21 Published 2010 Journal J Neural Transm Section Body Doc Link PMC3000910 Disease Relevance 0.53 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox